A Phase 3 interventional study of LentiGlobin BB305 Drug Product in Beta-Thalassemia, sponsored by bluebird bio. Completed at 9 sites in 6 countries. Open to participants aged 0 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-03-07.
Sponsored by bluebird bio · Phase 3, Interventional, and Treatment
This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 18 participants less than or equal to (\<=) 50 years of age with transfusion-dependent β-thalassemia (TDT), who have a β0/β0, β0/IVS-I-110, or IVS-I-110/IVS-I-110 genotype. The study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin BB305 Drug Product.
416 studies on the registry are indexed under Thalassemia; 67 are open to participants now.
This study's enrollment of 19 is below the median of 37 across 277 interventional studies indexed under Thalassemia.
Browse Thalassemia studies →bluebird bio is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
Genetic: LentiGlobin BB305 Drug Product
LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Also known as: betibeglogene autotemcel
Percentage of Participants Who Have Achieved Transfusion Independence (TI)
TI was defined as a weighted average hemoglobin (Hb) \>= 9 grams per deciliter (g/dL) without any packed red blood cell (pRBC) transfusions for a continuous period of \>= 12 months at any time during the study after drug product infusion.
Time frame: From 12 to 24 months post-transplant
Percentage of Participants Who Have Achieved Transfusion Independence (TI) at Month 24
TI was defined as a weighted average hemoglobin (Hb) \>= 9 grams per deciliter (g/dL) without any packed red blood cell (pRBC) transfusions for a continuous period of \>= 12 months at any time during the study after drug product infusion.
Time frame: At Month 24 post-transplant
Duration of Transfusion Independence (TI)
Duration of TI was calculated as the time from the start of TI (i.e. first Hb \>=9 with no transfusions in the preceding 60 days) up to the last available Hb at which the TI criteria are still met using Kaplan-Meier methodology.
Time frame: From start of TI up to Month 24 (actual maximum time frame of up to approximately 25 months due to visit window)
Time From Drug Product Infusion to Achievement of Transfusion Independence (TI)
Time from drug product infusion to achievement of TI was calculated as the time from drug product infusion to the first hemoglobin at which a participant can be declared as TI (that is to 'start of TI + \>= 12 months', dependent on Hb lab schedule).
Time frame: From drug product infusion to start of TI (up to Month 24 [actual maximum time frame of up to approximately 25 months due to visit window])
Weighted Average Hemoglobin (Hb) During Transfusion Independence (TI)
Weighted average Hb was defined as the weighted average of Hb values without any pRBC transfusions in the proceeding 60 days for a given subject. Ratio of the time between two Hb values and the time between the first and the last Hb values was used as the weight for calculation.
Time frame: Timeframe varied by subject. For a given subject, the endpoint was calculated from 60 days after the last pRBC transfusion (so transfused blood did not confound the weighted average calculation) through the Month 24 Visit for that subject.
Percentage of Participants Who Meet the Definition of Transfusion Reduction (TR)
TR was defined as demonstration of a 60 percent (%) reduction in the annualized volume of pRBC transfusion requirements (in milliliter per kilogram \[mL/kg\]) in the post-treatment time period from 12 Months post-drug product infusion through Month 24 compared to the annualized mL/kg pRBC transfusion requirement during the 24 months prior to study enrollment.
Time frame: From 12 to 24 months post-transplant
Percentage of Participants Who Had a Reduction of At Least 50%, 60%, 75%, 90% or 100% in the Annualized pRBCs Transfusion Volume
Percentage of participants with a reduction in the annualized mL/kg pRBCs transfused from 12 months post-drug product infusion through Month 24 (approximately a 12-month period) of at least 50%, 60%, 75%, 90% or 100% compared to the annualized mL/kg pRBC transfusion requirement during the 24 months prior to enrollment.
Time frame: 12 months post-drug product infusion through Month 24
Annualized Number of pRBC Transfusions
Annualized number of pRBC transfusions from 12 months post-drug product infusion through Month 24 was reported.
Time frame: From 12 months post-drug product infusion through Month 24
Annualized Volume of pRBC Transfusions
Annualized volume of pRBC transfusions from 12 months post-drug product infusion through Month 24 compared to the annualized volume of transfusions during the 24 months prior to enrollment.
Time frame: From 12 to 24 months post-transplant
Time From Drug Product Infusion to Last pRBC Transfusion
Time from drug product infusion to last pRBC transfusion was reported.
Time frame: From start of drug product infusion up to Month 24
Time From Last pRBC Transfusion to 24 Months
Time From Last pRBC Transfusion to the Month 24 was reported.
Time frame: From last pRBC Transfusion up to Month 24 (actual maximum time frame of up to approximately 27 months due to visit window)
Weighted Average Nadir Hemoglobin (Hb)
The weighted average nadir Hb was defined as the most recent Hb prior to each pRBC transfusion, on the day of transfusion or within 3 days and, if there was a period of more than 60 days without transfusion, all Hb records between Day 61 and last follow-up or next transfusion (inclusive) was included. The weighted average nadir Hb during the period of 12 months post-drug product infusion to Month 24 was compared to the weighted average nadir Hb during the 24 months prior to enrollment.
Time frame: 12 months post-drug product infusion through Month 24
Unsupported Total Hb Levels at Month 6, 9, 12, 18 and 24
Unsupported total Hb level was defined as the total Hb measurement level without any acute or chronic pRBC transfusions within 60 days prior to the measurement date.
Time frame: At Month 6, 9, 12, 18 and 24
Number of Participants With Unsupported Total Hb Levels (>=10 g/dL, >=11 g/dL, >=12 g/dL, >=13 g/dL, and >=14 g/dL) at Months 6, 9, 12, 18 and 24
Number of participants with unsupported total Hb levels (\>=10 g/dL, \>=11 g/dL, \>=12 g/dL, \>=13 g/dL, and \>=14 g/dL) meeting the thresholds were reported at Months 6, 9, 12, 18 and 24. Participants were evaluable if they had an unsupported total Hb measurement at the specific timepoint, where unsupported total Hb level is defined as the total Hb measurement level without any acute or chronic pRBC transfusions within 60 days prior to the measurement date.
Time frame: At Months 6, 9, 12, 18 and 24
Percentage of Participants Who Have Not Received Chelation Therapy for At Least 6 Months Following Drug Product Infusion
Percentage of participants who have not received chelation therapy for at least 6 months following drug product infusion were reported.
Time frame: From 6 to 24 months
Time From Last Iron Chelation Use to Last Follow-up
Time from last iron chelation use to last follow-up to 24 months was reported.
Time frame: From last Iron Chelation up to Month 24 (actual maximum time frame of up to approximately 29 months due to visit window)
Number of Participants Who Used Therapeutic Phlebotomy Post Drug Product Infusion
Therapeutic phlebotomy could be used in lieu of chelation in participants who had Hb consistently \>= 11 g/dL and who were no longer receiving regular transfusions, at the discretion of the investigator. Number of participants who used therapeutic phlebotomy post Drug Product infusion for up to Month 24 were reported.
Time frame: From drug product infusion through Month 24
Annualized Phlebotomy Therapy Usage Following Drug Product Infusion
Annualized phlebotomy therapy usage (number of procedures per year, calculated from DP infusion through last follow-up) were reported.
Time frame: From drug product infusion through Month 24
Change From Baseline in Liver Iron Content by Magnetic Resonance Imaging (MRI)
Change From Baseline in Liver Iron Content by MRI at Months 12 and 24 were reported. Baseline is defined as value closest to but prior to conditioning.
Time frame: Baseline, Month 12 and 24
Change From Baseline in Cardiac T2* on MRI
Change From Baseline in Cardiac T2\* on MRI from Baseline, Month 12 and 24 was reported.
Time frame: Baseline, Months 12 and 24
Change From Baseline in Serum Ferritin
Serum ferritin was commonly used for an indirect estimation of body iron stores. Although sensitive, it is not specific for iron overload as it can be elevated in a variety of infectious and inflammatory states, and in the presence of cytolysis. Change from baseline in serum ferritin at Months 12 and 24 was reported.
Time frame: Baseline, Month 12 and 24
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Total Scores at Months 12 and 24
PedsQL GCS designed to measure health-related quality of life in pediatric and adolescents (2-18 years). It encompassed 4 dimensions of functioning (physical \[8 items\], emotional \[5 items\], social \[5 items\], school \[3 items\]). Age groups: Toddler (2-4 years), Young pediatric (5-7 years), Pediatric (8-12 years), Teens (13-18 years). The questionnaire was also completed by parent/caregiver to assess parents' perceptions of their children's quality of life. The Toddler group consisted of 21 items, using a 5-point Likert scale (0 to 4); all other groups consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for young pediatric, a 5-point Likert scale for pediatric and teens groups. All reported scores were transformed on a scale from 0 to 100 for each domain where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores correspond with higher quality of life.
Time frame: Baseline, Month 12 and 24
Change From Baseline in EuroQol Quality of Life 5-Dimension Youth Scale (EQ-5D-Y) VAS Health Status at Months 12 and 24
EQ-5D is a validated, standardized, generic instrument that was most widely used preference based health related quality of life questionnaire in cost effectiveness and health technologies assessment. EQ-5D-Y was a version of instrument specifically developed and validated for use by youths aged 12 through 17 years. The EQ-5D-Y visual analog scale (VAS) consisted of a 20-cm vertical VAS, with anchors of 0 (worst imaginable health state) and 100 (best imaginable health state). Respondents were asked to rate their own health state today by drawing a line from a box containing these words to the point on the scale that they felt most accurately reflected their current health state. The VAS was reported (raw data) on a scale of 0-100 where 0= death and 100= perfect health. Higher scores corresponded with higher quality of life.
Time frame: Baseline, Months 12 and 24
Change From Baseline in EuroQol Quality of Life 5-Dimension Adult Scale (EQ-5D-3L) VAS Heath Status Score at Months 12 and 24
EQ-5D is a validated, standardized, generic instrument that was most widely used preference based health related quality of life (HRQoL) questionnaire in cost effectiveness and health technologies assessment. Participants age \>=18 at time of informed consent were eligible to complete the EQ-5D-3L visual analog scale (VAS) which consisted of a 20-cm vertical VAS, with anchors of 0 (worst imaginable health state) and 100 (best imaginable health state). Respondents were asked to rate their own health state today by drawing a line from a box containing these words to the point on the scale that they felt most accurately reflected their current health state. The VAS was reported (raw data) on a scale of 0-100 where 0= death and 100= perfect health. Negative change in score indicated decrease in quality of life (as measured by EQ5D VAS) from baseline.
Time frame: Baseline, Months 12 and 24
Change From Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Questionnaire Total Score
FACT-BMT is assessed bone marrow transplant related quality of life in adults. Total score was sum of sub-scale scores for 5 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and Bone Marrow Transplantation Subscale. Each item scored on a 5-point Likert scale based on participant agreement with each statement: 0 for "not at all," 1 for "a little bit," 2 for "somewhat," 3 for "quite a bit," and 4 for "very much. Reported scores were transformed as follows: After taking into account reverse scores for questions constructed in negative form, subscale score for each domain was calculated by multiplying sum of item scores by number of items in subscale, then dividing by number of items answered. Total score was sum of subscale total added together and ranges from 0-148. Higher scores corresponded with higher quality of life.
Time frame: Baseline, Months 12 and 24
Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores) at Months 12 and 24
SF-36 was designed to measure health-related quality of life in adults. The instrument consisted of 36 items that were aggregated into 8 multi-item scales (physical functioning \[1=yes, limited a lot, to 3=no, not limited at all\], role-physical \[1=all of time, to 5=none of time\], bodily pain \[1=very severe, to 6=none\], general health \[1=poor, to 5=excellent\], vitality \[1=none of time, to 5=all of time\], social functioning \[1=all of time, to 5=none of time\], role emotional \[1=all of time, to 5=none of time\] and mental health \[1=all of time, to 5=none of the time\]). The 8 scales were summarized as Physical Component Summary (PCS) score (physical functioning, role-physical, bodily pain, general health scales) and Mental Component Summary (MCS) score (vitality, social functioning, role-emotional, mental health scales). Reported summary scores were transformed on a scale from 0-100 (higher scores corresponded with higher quality of life), with change from baseline results being presented.
Time frame: Baseline, Months 12 and 24
The study was conducted at 9 study centers in France, Germany, Greece, Italy, United Kingdom, and United States, of which 8 active centers had enrolled participants from 08 June 2017 to 15 November 2022.
| Milestone | LentiGlobin BB305 Drug Product |
|---|---|
| Started | 19 |
| Intent-to-treat (itt) population | 19 |
| Transplant population (tp) | 18 |
| Completed | 18 |
| Not completed | 1 |
| Withdrew: Withdrew consent prior to conditioning | 1 |
TI was defined as a weighted average hemoglobin (Hb) \>= 9 grams per deciliter (g/dL) without any packed red blood cell (pRBC) transfusions for a continuous period of \>= 12 months at any time during the study after drug product infusion.
| Percentage of participants | LentiGlobin BB305 Drug Product |
|---|---|
| Percentage of Participants Who Have Achieved Transfusion Independence (TI) | 88.9 (65.3 to 98.6) |
TI was defined as a weighted average hemoglobin (Hb) \>= 9 grams per deciliter (g/dL) without any packed red blood cell (pRBC) transfusions for a continuous period of \>= 12 months at any time during the study after drug product infusion.
| Percentage of participants | LentiGlobin BB305 Drug Product |
|---|---|
| Percentage of Participants Who Have Achieved Transfusion Independence (TI) at Month 24 | 88.9 (65.3 to 98.6) |
Duration of TI was calculated as the time from the start of TI (i.e. first Hb \>=9 with no transfusions in the preceding 60 days) up to the last available Hb at which the TI criteria are still met using Kaplan-Meier methodology.
| Months | LentiGlobin BB305 Drug Product |
|---|---|
| Duration of Transfusion Independence (TI) | 20.86 (13.1 to 25.4) |
Time from drug product infusion to achievement of TI was calculated as the time from drug product infusion to the first hemoglobin at which a participant can be declared as TI (that is to 'start of TI + \>= 12 months', dependent on Hb lab schedule).
| Months | LentiGlobin BB305 Drug Product |
|---|---|
| Time From Drug Product Infusion to Achievement of Transfusion Independence (TI) | 15.67 (14.8 to 24.5) |
Weighted average Hb was defined as the weighted average of Hb values without any pRBC transfusions in the proceeding 60 days for a given subject. Ratio of the time between two Hb values and the time between the first and the last Hb values was used as the weight for calculation.
| gram per deciliter (g/dL) | LentiGlobin BB305 Drug Product |
|---|---|
| Weighted Average Hemoglobin (Hb) During Transfusion Independence (TI) | 10.817 ± 1.2535 |
TR was defined as demonstration of a 60 percent (%) reduction in the annualized volume of pRBC transfusion requirements (in milliliter per kilogram \[mL/kg\]) in the post-treatment time period from 12 Months post-drug product infusion through Month 24 compared to the annualized mL/kg pRBC transfusion requirement during the 24 months prior to study enrollment.
| Percentage of participants | LentiGlobin BB305 Drug Product |
|---|---|
| Percentage of Participants Who Meet the Definition of Transfusion Reduction (TR) | 94.4 (72.7 to 99.9) |
Percentage of participants with a reduction in the annualized mL/kg pRBCs transfused from 12 months post-drug product infusion through Month 24 (approximately a 12-month period) of at least 50%, 60%, 75%, 90% or 100% compared to the annualized mL/kg pRBC transfusion requirement during the 24 months prior to enrollment.
| Percentage of participants | LentiGlobin BB305 Drug Product |
|---|---|
| Reduction at >= 50% | 94.4 (72.7 to 99.9) |
| Reduction at >= 60% | 94.4 (72.7 to 99.9) |
| Reduction at >= 75% | 94.4 (72.7 to 99.9) |
| Reduction at >= 90% | 94.4 (72.7 to 99.9) |
| Reduction at 100% | 88.9 (65.3 to 98.6) |
Annualized number of pRBC transfusions from 12 months post-drug product infusion through Month 24 was reported.
| pRBC transfusions per year | LentiGlobin BB305 Drug Product |
|---|---|
| Annualized Number of pRBC Transfusions | 0.68 ± 2.701 |
Annualized volume of pRBC transfusions from 12 months post-drug product infusion through Month 24 compared to the annualized volume of transfusions during the 24 months prior to enrollment.
| milliliter/kilogram/year (mL/kg/year) | LentiGlobin BB305 Drug Product |
|---|---|
| Annualized Volume of pRBC Transfusions | 11.589 ± 47.4080 |
Time from drug product infusion to last pRBC transfusion was reported.
| months | LentiGlobin BB305 Drug Product |
|---|---|
| Time From Drug Product Infusion to Last pRBC Transfusion | 0.986 (0.00 to 23.36) |
Time From Last pRBC Transfusion to the Month 24 was reported.
| Months | LentiGlobin BB305 Drug Product |
|---|---|
| Time From Last pRBC Transfusion to 24 Months | 23.211 (0.16 to 27.47) |
The weighted average nadir Hb was defined as the most recent Hb prior to each pRBC transfusion, on the day of transfusion or within 3 days and, if there was a period of more than 60 days without transfusion, all Hb records between Day 61 and last follow-up or next transfusion (inclusive) was included. The weighted average nadir Hb during the period of 12 months post-drug product infusion to Month 24 was compared to the weighted average nadir Hb during the 24 months prior to enrollment.
| g/dL | LentiGlobin BB305 Drug Product |
|---|---|
| Weighted Average Nadir Hemoglobin (Hb) | 10.653 ± 1.5096 |
Unsupported total Hb level was defined as the total Hb measurement level without any acute or chronic pRBC transfusions within 60 days prior to the measurement date.
| g/dL | LentiGlobin BB305 Drug Product |
|---|---|
| At Month 6 | 10.41 ± 1.253 |
| At Month 9 | 10.61 ± 1.338 |
| At Month 12 | 10.65 ± 1.619 |
| At Month 18 | 11.00 ± 1.483 |
| At Month 24 | 10.82 ± 1.580 |
Number of participants with unsupported total Hb levels (\>=10 g/dL, \>=11 g/dL, \>=12 g/dL, \>=13 g/dL, and \>=14 g/dL) meeting the thresholds were reported at Months 6, 9, 12, 18 and 24. Participants were evaluable if they had an unsupported total Hb measurement at the specific timepoint, where unsupported total Hb level is defined as the total Hb measurement level without any acute or chronic pRBC transfusions within 60 days prior to the measurement date.
| Participants | LentiGlobin BB305 Drug Product |
|---|---|
| At Month 6 (>=10 g/dL) | 11 |
| At Month 6 (>=11 g/dL) | 4 |
| At Month 6 (>=12 g/dL) | 3 |
| At Month 6 (>=13 g/dL) | 1 |
| At Month 6 (>=14 g/dL) | 0 |
| At Month 9 (>=10 g/dL) | 13 |
| At Month 9 (>=11 g/dL) | 5 |
| At Month 9 (>=12 g/dL) | 3 |
| At Month 9 (>=13 g/dL) | 1 |
| At Month 9 (>=14 g/dL) | 0 |
| At Month 12 (>=10 g/dL) | 12 |
| At Month 12 (>=11 g/dL) | 6 |
| At Month 12 (>=12 g/dL) | 3 |
| At Month 12 (>=13 g/dL) | 2 |
| At Month 12 (>=14 g/dL) | 1 |
| At Month 18 (>=10 g/dL) | 13 |
| At Month 18 (>=11 g/dL) | 5 |
| At Month 18 (>=12 g/dL) | 3 |
| At Month 18 (>=13 g/dL) | 3 |
| At Month 18 (>=14 g/dL) | 0 |
| At Month 24 (>=10 g/dL) | 10 |
| At Month 24 (>=11 g/dL) | 7 |
| At Month 24 (>=12 g/dL) | 3 |
| At Month 24 (>=13 g/dL) | 3 |
| At Month 24 (>=14 g/dL) | 1 |
Percentage of participants who have not received chelation therapy for at least 6 months following drug product infusion were reported.
| Percentage of participants | LentiGlobin BB305 Drug Product |
|---|---|
| Percentage of Participants Who Have Not Received Chelation Therapy for At Least 6 Months Following Drug Product Infusion | 61.1 |
Time from last iron chelation use to last follow-up to 24 months was reported.
| Months | LentiGlobin BB305 Drug Product |
|---|---|
| Time From Last Iron Chelation Use to Last Follow-up | 17.81 (0.3 to 28.9) |
Therapeutic phlebotomy could be used in lieu of chelation in participants who had Hb consistently \>= 11 g/dL and who were no longer receiving regular transfusions, at the discretion of the investigator. Number of participants who used therapeutic phlebotomy post Drug Product infusion for up to Month 24 were reported.
| Participants | LentiGlobin BB305 Drug Product |
|---|---|
| Number of Participants Who Used Therapeutic Phlebotomy Post Drug Product Infusion | 2 |
Annualized phlebotomy therapy usage (number of procedures per year, calculated from DP infusion through last follow-up) were reported.
| Number of procedures per year | LentiGlobin BB305 Drug Product |
|---|---|
| Annualized Phlebotomy Therapy Usage Following Drug Product Infusion | 4.22 ± 3.192 |
Change From Baseline in Liver Iron Content by MRI at Months 12 and 24 were reported. Baseline is defined as value closest to but prior to conditioning.
| milligram per gram (mg/g) | LentiGlobin BB305 Drug Product |
|---|---|
| Change at Month 12 | 3.171 ± 5.4134 |
| Change at Month 24 | 1.033 ± 4.4407 |
Change From Baseline in Cardiac T2\* on MRI from Baseline, Month 12 and 24 was reported.
| milliseconds | LentiGlobin BB305 Drug Product |
|---|---|
| Change at Month 12 | -0.2 (-27 to 7) |
| Change at Month 24 | 0.2 (-33 to 12) |
Serum ferritin was commonly used for an indirect estimation of body iron stores. Although sensitive, it is not specific for iron overload as it can be elevated in a variety of infectious and inflammatory states, and in the presence of cytolysis. Change from baseline in serum ferritin at Months 12 and 24 was reported.
| picomole per liter (pmol/L) | LentiGlobin BB305 Drug Product |
|---|---|
| Change at Month 12 | 87.3 ± 1302.76 |
| Change at Month 24 | -605.2 ± 1716.90 |
PedsQL GCS designed to measure health-related quality of life in pediatric and adolescents (2-18 years). It encompassed 4 dimensions of functioning (physical \[8 items\], emotional \[5 items\], social \[5 items\], school \[3 items\]). Age groups: Toddler (2-4 years), Young pediatric (5-7 years), Pediatric (8-12 years), Teens (13-18 years). The questionnaire was also completed by parent/caregiver to assess parents' perceptions of their children's quality of life. The Toddler group consisted of 21 items, using a 5-point Likert scale (0 to 4); all other groups consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for young pediatric, a 5-point Likert scale for pediatric and teens groups. All reported scores were transformed on a scale from 0 to 100 for each domain where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores correspond with higher quality of life.
| Score on a scale | LentiGlobin BB305 Drug Product |
|---|---|
| Parent total score: Change at Month 12 | -6.20 ± 12.948 |
| Parent total score: Change at Month 24 | -3.49 ± 19.621 |
| Patient total score: Change at Month 12 | 2.96 ± 14.857 |
| Patient total score: Change at Month 24 | 4.84 ± 11.321 |
EQ-5D is a validated, standardized, generic instrument that was most widely used preference based health related quality of life questionnaire in cost effectiveness and health technologies assessment. EQ-5D-Y was a version of instrument specifically developed and validated for use by youths aged 12 through 17 years. The EQ-5D-Y visual analog scale (VAS) consisted of a 20-cm vertical VAS, with anchors of 0 (worst imaginable health state) and 100 (best imaginable health state). Respondents were asked to rate their own health state today by drawing a line from a box containing these words to the point on the scale that they felt most accurately reflected their current health state. The VAS was reported (raw data) on a scale of 0-100 where 0= death and 100= perfect health. Higher scores corresponded with higher quality of life.
| Score on a scale | LentiGlobin BB305 Drug Product |
|---|---|
| Health State: Change at Month 12 | 0.3 ± 11.91 |
| Health State: Change at Month 24 | 2.0 ± 12.33 |
EQ-5D is a validated, standardized, generic instrument that was most widely used preference based health related quality of life (HRQoL) questionnaire in cost effectiveness and health technologies assessment. Participants age \>=18 at time of informed consent were eligible to complete the EQ-5D-3L visual analog scale (VAS) which consisted of a 20-cm vertical VAS, with anchors of 0 (worst imaginable health state) and 100 (best imaginable health state). Respondents were asked to rate their own health state today by drawing a line from a box containing these words to the point on the scale that they felt most accurately reflected their current health state. The VAS was reported (raw data) on a scale of 0-100 where 0= death and 100= perfect health. Negative change in score indicated decrease in quality of life (as measured by EQ5D VAS) from baseline.
| Score on a scale | LentiGlobin BB305 Drug Product |
|---|---|
| Health State: Change at Month 12 | -3.6 ± 13.13 |
| Health State: Change at Month 24 | -2.4 ± 10.50 |
FACT-BMT is assessed bone marrow transplant related quality of life in adults. Total score was sum of sub-scale scores for 5 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and Bone Marrow Transplantation Subscale. Each item scored on a 5-point Likert scale based on participant agreement with each statement: 0 for "not at all," 1 for "a little bit," 2 for "somewhat," 3 for "quite a bit," and 4 for "very much. Reported scores were transformed as follows: After taking into account reverse scores for questions constructed in negative form, subscale score for each domain was calculated by multiplying sum of item scores by number of items in subscale, then dividing by number of items answered. Total score was sum of subscale total added together and ranges from 0-148. Higher scores corresponded with higher quality of life.
| Score on a scale | LentiGlobin BB305 Drug Product |
|---|---|
| Total Score: Change at Month 12 | 0.33 ± 6.716 |
| Total Score: Change at Month 24 | 2.58 ± 4.246 |
SF-36 was designed to measure health-related quality of life in adults. The instrument consisted of 36 items that were aggregated into 8 multi-item scales (physical functioning \[1=yes, limited a lot, to 3=no, not limited at all\], role-physical \[1=all of time, to 5=none of time\], bodily pain \[1=very severe, to 6=none\], general health \[1=poor, to 5=excellent\], vitality \[1=none of time, to 5=all of time\], social functioning \[1=all of time, to 5=none of time\], role emotional \[1=all of time, to 5=none of time\] and mental health \[1=all of time, to 5=none of the time\]). The 8 scales were summarized as Physical Component Summary (PCS) score (physical functioning, role-physical, bodily pain, general health scales) and Mental Component Summary (MCS) score (vitality, social functioning, role-emotional, mental health scales). Reported summary scores were transformed on a scale from 0-100 (higher scores corresponded with higher quality of life), with change from baseline results being presented.
| Score on a scale | LentiGlobin BB305 Drug Product |
|---|---|
| Physical Component Summary: Change at Month 12 | -0.89 ± 10.289 |
| Physical Component Summary: Change at Month 24 | 1.09 ± 8.167 |
| Mental Component Summary: Change at Month 12 | 2.42 ± 7.637 |
| Mental Component Summary: Change at Month 24 | 2.08 ± 7.281 |
Collected over From date of informed consent to the date of last followup (an average of 32.5 months of followup for ITT subjects).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LentiGlobin BB305 Drug Product | 0/19 (0%) | 6/19 (31.6%) | 19/19 (100%) |
| Event | LentiGlobin BB305 Drug Product |
|---|---|
| PyrexiaGeneral disorders | 3/19 |
| Cardiac failure congestiveCardiac disorders | 1/19 |
| HeadacheNervous system disorders | 1/19 |
| NeutropeniaBlood and lymphatic system disorders | 1/19 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/19 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/19 |
| Gastric ulcer perforationGastrointestinal disorders | 1/19 |
| StomatitisGastrointestinal disorders | 1/19 |
| Bartholin's cystReproductive system and breast disorders | 1/19 |
| Soft tissue infectionInfections and infestations | 1/19 |
| Event | LentiGlobin BB305 Drug Product |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 17/19 |
| NeutropeniaBlood and lymphatic system disorders | 16/19 |
| AnaemiaBlood and lymphatic system disorders | 15/19 |
| VomitingGastrointestinal disorders | 12/19 |
| AlopeciaSkin and subcutaneous tissue disorders | 12/19 |
| Febrile neutropeniaBlood and lymphatic system disorders | 11/19 |
| StomatitisGastrointestinal disorders | 11/19 |
| Procedural painInjury, poisoning and procedural complications | 9/19 |
| NauseaGastrointestinal disorders | 9/19 |
| Alanine aminotransferase increasedInvestigations | 8/19 |
Data are analyzed at times based on ITT population which included all 19 participants who initiated any study procedures, beginning with mobilization by G-CSF and/or plerixafor.
| Age, Continuous(Years) | LentiGlobin BB305 Drug Product |
|---|---|
| Mean | 14.8 ± 8.77 |
| Sex: Female, Male(Participants) | LentiGlobin BB305 Drug Product |
|---|---|
| Female | 9 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | LentiGlobin BB305 Drug Product |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 18 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | LentiGlobin BB305 Drug Product |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 8 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Bluebird bio is committed to transparency. Appropriately de-identified patient-level datasets and supporting documents may be shared (if contractually or otherwise legally permitted) following completion of this study, submission of all applicable regulatory submissions and consistent with criteria established by bluebird bio and/or industry best practices to protect confidential information and maintain the privacy of study participants. For enquiries, please contact us at datasharing@bluebirdbio.com.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
bluebird bio